| Document |
Document Title |
|
WO/2008/049644A1 |
The present invention relates to nucleoside analogues and more particularly to labeled nucleoside analogues. It has been found new thymidine analogues can be stably labeled with a detectable label moiety. Further the present invention re...
|
|
WO/2008/051285A2 |
The invention relates to a method of identifying a specific fungal species in patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the fungal species from the patient tissue or body fluid, ampl...
|
|
WO/2008/045419A1 |
The present process provides an improved method for the preparation of 4- amino-l-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-hydroxymethyl-3-
methyl- tetrahydro-furan-2-yl)-lH-pyrimidin-2-one of the formula (IV) which is a potent inhibitor of H...
|
|
WO/2008/043704A1 |
4-Amino-1-((2R,3S,4S,5R)-5-azido-4hydroxy-5-hydroxymethyl-3-
methyl-tetrahyclrofuran-2- yl)-1 H-pyrimidin-2-one(22) are hepatitis C (HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting HCV and treating ...
|
|
WO/2008/043426A2 |
The invention relates to nucleotide analogues containing a sterically-hindered macromolecular ligand and a marker. Said nucleotide analogues can be used for enzymatic synthesis and sequencing of nucleic acids.
|
|
WO/2008/038094A2 |
The invention relates to a process for the preparation of pure adenosine. The invention also relates to pharmaceutical compositions that include the pure adenosine.
|
|
WO/2008/037036A2 |
The present invention provides for oligonucleotide arrays wherein the oligonucleotides comprise six- membered sugar-ring nucleosides, especially tetrahydropyran nucleosides, more specifically altritol nucleosides. The present invention a...
|
|
WO/2008/039997A2 |
Provided are nucleotide-label conjugates and related compounds in which a label, such as a fluorescent dye, is linked to a nucleobase directly or indirectly by a linker. In some embodiments, the linker comprises a backbone comprising at ...
|
|
WO/2008/036841A2 |
Provided herein are tripartite oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene. The tripartite oligonucleotide complexes of the disclosure may include a conjugate moiety that fac...
|
|
WO/2008/036825A2 |
Provided herein are duplex oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene without the aid of a transfection reagent(s). The duplex oligonucleotide complexes of the disclosure in...
|
|
WO/2008/032103A2 |
This invention relates to a process for the preparation of an (Rp)-8-substituted adenosine-3',5'-cyclic phosphorothioic acid, or a salt or ester thereof, which comprises P-amidating 8-bromoadenosine-3',5'-cyclic phosphoric acid, and reac...
|
|
WO/2008/028050A2 |
The present invention relates to methods of use of glycosyltransferases and related novel compounds. The invention exploits the reversibility of glycosyltransferases to generate new sugars, unnatural biomolecules and numerous one-pot rea...
|
|
WO/2008/025886A1 |
The invention relates to novel chelating agents and metal chelates containing 1,2,3-triazolyl subunits, and their conjugates with biomolecules or particles. The invention concerns also a process for the preparation of the novel chelating...
|
|
WO/2008/026729A1 |
[PROBLEMS] To provide a novel, useful therapeutic agent for pigmented villonodular synovitis or giant cell tumor of tendon sheath or bone. [MEANS FOR SOLVING PROBLEMS] Disclosed is a therapeutic agent for pigmented villonodular synovitis...
|
|
WO/2008/025160A1 |
The present invention provides oxepane nucleosides, oxepane nucleotides, modified oxepane nucleotides, oligonucleotides, methods for making and uses for modulating gene expression. The oxepane nucleoside having formula I : wherein B is a...
|
|
WO/2008/022469A1 |
The invention relates to arabinose modified nucleoside 5' triphosphates and to the biosynthesis and amplification of oligonucleotides containing and/or from templates containing arabinose modified nucleosides. The invention further relat...
|
|
WO/2008/020560A1 |
Disclosed is an antibacterial agent having an excellent antibacterial activity against Mycobacterium avium subsp. paratuberculosis. The antibacterial agent has an antibacterial activity against comprises a caprazamycin derivative represe...
|
|
WO/2008/016906A2 |
The invention provides nucleotide analogs for use in sequencing nucleic acid molecules.
|
|
WO/2008/016909A2 |
The invention provides nucleotides of Formula (I) for use in sequencing nucleic acid molecules. Formula (I) wherein, B is selected from the group consisting of a purine, a pyrimidine, and analogs thereof, R1 is selected from the group co...
|
|
WO/2008/016244A1 |
Disclosed herein are novel naphthalene-2-carboxylate derivatives of Formula (I), which are useful for the synthesis of gemcitabine, as well as a preparation method. The novel derivatives have naphthalene-2-carboxlate as the hydroxy prote...
|
|
WO/2008/016079A1 |
The object is to provide a method for introducing a substituent (I) into a 2'-hydroxyl group of a ribose moiety in a ribonucleic acid derivative having a 3'-hydroxyl group and a 5'-hydroxyl group each protected by a silicon protecting gr...
|
|
WO/2008/016907A1 |
The invention provides nucleotide analogs for use in sequencing nucleic acid molecules.
|
|
WO/2008/013280A1 |
Disclosed is a compound represented by the formula (II) below, a pharmaceutically acceptable salt thereof, or a solvate thereof. Also disclosed are a pharmaceutical product, a pharmaceutical composition and the like, each containing the ...
|
|
WO/2008/012949A1 |
Pyrimidine nucleoside 5'-triphosphoric acid is converted into pyrimidine nucleoside 5'-(cyclic triphosphoric acid) with a condensation agent. Subsequently, the pyrimidine nucleoside 5'-(cyclic triphosphoric acid) obtained is reacted with...
|
|
WO/2008/013322A1 |
Novel indole derivatives of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 is fluorine, or chlorine, and R2 is hydrogen, or fluorine, which are SGLT inhibitors and are useful for treatment or prevention of diabetes...
|
|
WO/2008/012945A1 |
Disclosed is a compound which has excellent anti-tumor activity and excellent oral absorbability and is useful as an anti-tumor agent. Specifically disclosed is a 3'-ethynylcytidine derivative represented by the general formula (1) [wher...
|
|
WO/2008/013277A1 |
Disclosed is a compound represented by the formula (I) below, a prodrug thereof, or a pharmaceutically acceptable salt of any of them. Also disclosed are a pharmaceutical product, a pharmaceutical composition and the like, each containin...
|
|
WO/2008/014252A2 |
Smac mimetics that inhibit IAPs.
|
|
WO/2008/013321A1 |
Novel compounds of formula (A) or a pharmaceutically acceptable salt thereof: wherein symbols are as defined in claims, which are useful as SGLT inhibitors and for treatment of diabetes and related diseases.
|
|
WO/2008/010571A1 |
A pyrimidine nucleoside compound represented by the following general formula (1): [Chemical formula 1] (1) [wherein one of X and Y represents cyano and the other represents hydrogen, provided that i) R1 represents hydrogen and R2 repres...
|
|
WO/2008/011335A2 |
Compositions are provided comprising a family of peptides having binding specificity for metal, and their use to produce coating compositions. The coating compositions are used to deliver a pharmaceutically active agent to metal, and are...
|
|
WO/2008/011406A2 |
The invention is directed to carbonate and carbamate prodrugs of thiazolo[4,5-J]pyrimidine compounds, whose metabolized parent compound has immunomodulatory activity. The invention also relates to the therapeutic use of such prodrugs and...
|
|
WO/2008/006369A1 |
The present application discloses locked nucleoside compounds of the Formula I which act as antagonists of adenosine receptors, in particular the adenosine A3 receptor, and the use of such adenosine A3 receptor compounds in medicine, e.g...
|
|
WO/2008/007153A2 |
There are described compounds of formula (I): wherein, at least one of R1, R2 and R3 represents a group S-L- and the remainder represent H; S represents a binding group; L represents a linker chain; X represents O or NH; and pharmaceutic...
|
|
WO/2008/006563A1 |
Compounds of formula (I):or stereoisomers or pharmaceutically acceptable salts thereof, wherein W, R1,R 2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenos...
|
|
WO/2008/007728A1 |
Disclosed is a preparation comprising coenzyme A enclosed in a lipid membrane structure. The preparation enables to administer coenzyme A (which is easy to be degraded and unstable in the intestine) to a living body through a convenient ...
|
|
WO/2008/005542A2 |
A compound of Formula I, Formula II, Formula III, or Formula IV: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, therapeutic compositions containing such compounds, and therapeutic methods that include the administa...
|
|
WO/2008/000743A2 |
The invention relates to a method of improving oral drug absorption of adenosine analogues by the use of 2',3'-methylidene acetal adenosine pro-drugs and to the use of these pro-drugs as medicaments. The invention further relates to comp...
|
|
WO/2008/001718A1 |
A novel useful dehydroxylated fluorinating agent which comprises sulfuryl fluoride (SO2F2) and an organic base containing no free hydroxy group in the molecule. With the dehydroxylated fluorinating agent, optically active fluorinated der...
|
|
WO/2008/001109A2 |
A glycopeptide of the formula S-L-X-P, wherein: S is selected from an optionally protected monosaccharide, an optionally protected polysaccharide, a polyalkylene oxide chain and a group of the formula II, wherein R1 and R3 are independen...
|
|
WO/2008/001495A1 |
It is intended to provide an agent against psychosocial stresses which is highly safe and can be continuously taken, in particular, a novel agent against psychosocial stresses by which psychosocial stresses can be prevented or reduced. N...
|
|
WO/2008/000745A2 |
Compounds of formula (I) are disclosed. Their use as medicaments is described, in particular for the treatment of pain or inflammation. In said Fomula, when X=Y=Z=OH, R1 is OCH2CF2CF3, phenoxy (substituted with 3-(4-trifluoromethylphenyl...
|
|
WO/2007/149891A2 |
The present invention relates to novel crystal forms of an amide prodrug of gemcitabine, compositions thereof and methods for using.
|
|
WO/2007/145593A1 |
A compound according to the formula: The 2 ' -deoxy-2 ' -N, 4 ' -C- ethylene -bridged thymidine (aza-ENA-T) has been synthesized using a key cyclization step to give a fused piper idino skeleton in the chair conformation, whereas the pen...
|
|
WO/2007/144686A1 |
A method and composition for treating a host infected with flavivirus, pestivirus or hepacivirus comprising administering an effective fiavivirus, pestivirus or hepacivirus treatment amount of a described base- modified nucleoside or a p...
|
|
WO/2007/144168A1 |
An enzymatic procedure is described for the preparation of natural and modified nucleotides which are phosphorylated in position 5', starting from corresponding nucleoside precursors, according to the scheme reported below. Formula (I), ...
|
|
WO2007090553B1 |
Compounds useful as agonists of A2A adenosine receptors are described. Also described is a cosmetically acceptable composition having an agonists of A2A adenosine receptors where the composition is suitable to apply to human skin to redu...
|
|
WO/2007/135134A1 |
The invention relates to a maleate salt of 5-amino-3-(2'-3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazo
lo[4,5-d]pyrimidin-2-one and crystalline forms thereof, their production and usage, and pharmaceutical preparations containing these ...
|
|
WO/2007/136817A2 |
A2A agonists of formula (I) is provided, wherein R1, R2, R4, R5, X, Y, Z, n, p, and q are as described herein. Also provided are compositions comprising and methods of using compounds of formula (I).
|
|
WO/2007/135195A1 |
The present invention provides ectonucleotidase inhibitors represented by the following formula, including ecto-nucleotide triphosphate diphosphohydrolase (NTPDase) inhibitors and ecto-5'-nucleotidase (ecto-5'-NT) inhibitors, namely nucl...
|
